Last reviewed · How we verify
NNC0365-3769 (Mim8)
Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.
At a glance
| Generic name | NNC0365-3769 (Mim8) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Mim8 works by binding to and activating the GLP-1 receptor, which increases glucose-dependent insulin secretion, decreases glucagon secretion, and slows gastric emptying.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
Key clinical trials
- A Research Study Investigating Mim8 in People With Haemophilia A (PHASE2)
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors (PHASE3)
- A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) (PHASE3)
- A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors (PHASE3)
- A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge (PHASE1)
- A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC0365-3769 (Mim8) CI brief — competitive landscape report
- NNC0365-3769 (Mim8) updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI